Biovica (Q2 Initial take): Sales disappoint as key collaborations slip again - Redeye

Redeye provides an initial comment on Biovica’s Q2 2025/2026 report, which showed slower sales than anticipated but better cost control than expected. The company has decided to discontinue providing financial guidance, pending a more stable and predictable development in sales. The company’s collaborations with the large Integrated Delivery Network (IDN) and Tempus AI have been delayed once again. Overall, we view the stock’s double-digit decline as a reasonable market reaction.

Länk till analysen i sin helhet: https://www.redeye.se/research/1143803/biovica-q2-initial-take-sales-disappoint-as-key-collaborations-slip-again?utm_source=finwire&utm_medium=RSS